Pfizer falls after halting development of weight-loss pill danuglipron

Shares of drugmaker Pfizer PFE.N fall 3% to $21.25 premarket

Co says it has discontinued development of experimental weight-loss pill danuglipron

Says during a trial for the drug, a patient experienced potential drug-induced liver injury which resolved after the medication was stopped

Pfizer had been testing multiple doses of a once-a-day version of the oral drug candidate

Co will continue development of its experimental oral drug targeting a different hormone, GIPR, and other earlier obesity program research

Up to last close, stock down 17.4% YTD